Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile ...
Crestone announces positive Phase 2 trial results for CRS3123 in treating C. difficile infections, showing high clinical cure rates, low recurrence, and safety. NIAID funds $4.5 million for further studies.
Reference News
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)
Crestone announces positive Phase 2 results for CRS3123 in treating C. difficile infections (CDI), showing high clinical cure rates and lower recurrence compared to vancomycin. CRS3123, a novel drug, maintains gut microbiota, addressing urgent need for effective CDI therapy.
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile ...
Crestone announces positive Phase 2 trial results for CRS3123 in treating C. difficile infections, showing high clinical cure rates, low recurrence, and safety. NIAID funds $4.5 million for further studies.